Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Fennec Pharmaceuticals ( (TSE:FRX) ).
Fennec Pharmaceuticals will release its full-year and fourth-quarter 2025 financial results before U.S. markets open on March 24, 2026, followed by a management-hosted conference call and webcast for investors and analysts. The scheduled disclosure and discussion of financial and business performance come as the company advances commercialization of its pediatric ototoxicity therapy PEDMARK/PEDMARQSI across key global markets under long-term regulatory and patent protections, developments that are central to its growth trajectory and stakeholder expectations.
The most recent analyst rating on (TSE:FRX) stock is a Buy with a C$18.00 price target. To see the full list of analyst forecasts on Fennec Pharmaceuticals stock, see the TSE:FRX Stock Forecast page.
Spark’s Take on FRX Stock
According to Spark, TipRanks’ AI Analyst, FRX is a Neutral.
The score is primarily held back by mixed financial performance (TTM losses, renewed cash burn, and weak capitalization in the provided statements) and bearish technical signals (below key moving averages with negative MACD). Positive corporate events provide an offset through improved commercial momentum and clinical/financing progress, but not enough to outweigh the current financial and trend risks.
To see Spark’s full report on FRX stock, click here.
More about Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a commercial-stage specialty pharmaceutical company focused on combating ototoxicity in cancer patients receiving cisplatin-based chemotherapy. The company is centered on the commercialization of PEDMARK, approved by the FDA in 2022 and as PEDMARQSI in the EU and U.K., supported by an exclusive licensing deal with Norgine and patent protection extending to 2039.
Average Trading Volume: 827
Technical Sentiment Signal: Buy
Current Market Cap: C$356.6M
For an in-depth examination of FRX stock, go to TipRanks’ Overview page.